Comparative Pharmacology
Head-to-head clinical analysis: RAMELTEON versus ROZEREM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAMELTEON versus ROZEREM.
RAMELTEON vs ROZEREM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; promotes sleep by mimicking the effects of endogenous melatonin.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; modulates circadian rhythm and sleep-wake cycle.
8 mg orally once daily within 30 minutes of bedtime.
8 mg orally once daily, 30 minutes before bedtime, not to exceed 8 mg per day.
None Documented
None Documented
1-2.6 hours. The terminal half-life is short (mean ~1.3 hours) with no accumulation upon repeated dosing. Clinical context: Rapid clearance supports once-nightly dosing for sleep onset insomnia.
Clinical Note
moderateRamelteon + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Ramelteon."
Clinical Note
moderateRamelteon + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Ramelteon."
Clinical Note
moderateRamelteon + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ramelteon."
Clinical Note
moderateRamelteon + Cyclosporine
Ramelteon: 1-2.6 hours. Active metabolite M-II: 2-5 hours. Clinical context: Short half-life supports use for sleep initiation without significant next-day residual effects.
Ramelteon is extensively metabolized, primarily via CYP1A2 and to a lesser extent CYP2C9 and CYP3A4. Approximately 84% of the dose is excreted in urine as metabolites, with 4% as unchanged drug. Fecal excretion accounts for about 4% of the dose.
Primarily renal (about 84% of total clearance), with approximately 70-80% of an oral dose excreted in urine as glucuronide conjugates of ramelteon and its active metabolite M-II. Fecal excretion accounts for about 4%.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist
"The metabolism of Cyclosporine can be decreased when combined with Ramelteon."